Clinical trials: Retinal Neovascularization, active
Age-related Macular Degeneration (ARMD), Choroidal Neovascularization
Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization
Type 3 macular neovascularization (MNV) is a subtype of neovascular age-related macular degeneration accounting for 10-20% of cases, notable for high rates of bilateral involvement and risk of profound vision loss, particularly…
- Conditions
- Age-related Macular Degeneration (ARMD), Choroidal Neovascularization, Anti-vascular Endothelial Growth Factor
- Trial name
- NCT07187804
- Testing
- Intravitreal faricimab injection
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Kim's Eye Hospital
AMD, nAMD
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD).
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
- Trial name
- ATMOSPHERE (NCT04704921)
- Testing
- ABBV-RGX-314, Ranibizumab (LUCENTIS®)
- Where
- 89 sites in United States
- Volunteers
- 671 people
- Sponsor
- AbbVie
Exudative Macular Degeneration, Wet Age-related Macular Degeneration
MMP-9 Inhibition for Recalcitrant Wet AMD
Wet (or neovascular) form of age-related macular degeneration (wAMD) is the most common cause of blindness in the Western world.
- Trial name
- NCT04504123
- Testing
- Doxycycline Hyclate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Iowa
Maculopathy
AVIGA3 (Cohort 2.0)
Age-Macular Degeneration (AMD) is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a small area near the centre of the retina needed for sharp, central…
- Trial name
- AVIGA3 (NCT07255859)
- Testing
- Amsler Grid, AVIGA
- Where
- Singapore
- Volunteers
- 60 people
- Sponsor
- Tan Tock Seng Hospital
Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema
Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: Pain, Procedure Time, Patient Satisfaction, and Safety
This randomized controlled trial compares two techniques for eyelid retraction during intravitreal injection (IVI): an adjustable solid-blade eyelid speculum (Group A) and single-hand retraction of the upper eyelid with one…
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema, Retinal Vein Occlusion, Intravitreal Injections
- Trial name
- IVI-RETRACT (NCT07481500)
- Testing
- Eyelid Speculum Retraction, Cotton-Tipped Applicator Retraction
- Where
- Thailand
- Volunteers
- 129 people
- Sponsor
- Jakkrit Juhong
Retinal Artery Occlusions, Polypoidal Choroidal Vasculopathy
OCT in Rare Chorioretinal Diseases
This study will evaluate the total blood flow in the retina and choroid (structures in the back of the eye) by Doppler optical coherence tomography (OCT) and OCT angiography. Angiography is mapping of the blood vessels.
- Conditions
- Retinal Artery Occlusions, Polypoidal Choroidal Vasculopathy, Retinal Arterial Macroaneurysm, Juxtafoveal Telangiecasia
- Trial name
- NCT02141308
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Oregon Health and Science University
AMD - Age-Related Macular Degeneration
Comparison of the Sensibility of Swept Source Optical Coherence Tomography Devices in the Detection of Neovascularisation in Large Pigment Epithelium Detachments
The goal of this observational study is to compare swept source optical coherence tomography devices ability to detect macular neovascularisation when there is a large pigment epithelium detachment higher than 250 microns
- Trial name
- NCT07143526
- Testing
- Optical Coherence Tomography Angiography (OCT-A)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University of Trieste
AMD, nAMD
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD).
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
- Trial name
- ASCENT (NCT05407636)
- Testing
- ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
- Where
- 181 sites in United States, Canada and 8 more
- Volunteers
- 735 people
- Sponsor
- AbbVie
Choroidal Neovascularization, Mineralocorticoid Excess
Biomarkers and Choroidal Neovascularization
The aim of the study is to find biomarkers in the blood and aqueous humor of patients with type 1 choroidal neovascularization and correlate them with the response to anti-VEGF treatment.
- Trial name
- BioNéoRet (NCT04439708)
- Testing
- Blood and aqueous humor biomarker of treatment response
- Where
- 2 sites in France
- Volunteers
- 250 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Macular Degeneration, Age-Related Macular Degeneration
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person.
- Conditions
- Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
- Trial name
- MALBEC (NCT07440225)
- Testing
- Tiespectus, Aflibercept
- Where
- 132 sites in United States, Argentina and 10 more
- Volunteers
- 960 people
- Sponsor
- EyeBiotech Ltd.
Age - Related Macular Degeneration (AMD), Diabetic Macular Edema
Wide Field OCTA in Ocular Diseases
The main retinal diseases, whether or not associated with specific mutations genetic, cause progressive degeneration of vascular retinal structures and not vascular, resulting in decreased visual function.
- Conditions
- Age - Related Macular Degeneration (AMD), Diabetic Macular Edema, Diabetic Retinopathy, Myopia
- Trial name
- WOOD-2025 (NCT07298174)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Nearsightedness
Effect of Defocus in Soft Contact Lenses on Internal Retinal Vascularization
The purpose of this study is to gain a better understanding of the retinal vascular changes that occur in response to the optical effect of a myopic defocus daily disposable soft contact lens (MDSL) in a group of healthy young…
- Trial name
- NCT06527274
- Testing
- Experimental: Myopic defocus soft lens design (MDSL), Active Comparator: Single vision soft lens design (SVSL
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Université de Montréal
Bronchopulmonary Dysplasia
OCTA Evaluation of Retinal Vascularization in Preterm Infants With or Without Bronchopulmonary Dysplasia
Retinal vascularization in humans develops between the 16th and 36th weeks of amenorrhea, in a centrifugal pattern starting from the optic disc.
- Trial name
- OCTA_BRO (NCT07586683)
- Testing
- OCT Angiography
- Where
- France
- Volunteers
- 56 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Polypoidal Choroidal Vasculopathy (PCV), Age Related Macular Degeneration
Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy
To evaluate the Efficacy of a personalized treat-and-extend regimen of faricimab for treatment-naive polypoidal choroidal vasculopathy
- Trial name
- HANGANG (NCT07461441)
- Testing
- Faricimab Injection [Vabysmo]
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Yeungnam University College of Medicine
Neovascular Age-related Macular Degeneration
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
Neovascular or wet age-related macular degeneration (nAMD) is a degenerative ocular disease associated with the infiltration of abnormal blood vessels in the retina from the underlying choroid layer and is a leading cause of…
- Trial name
- NCT05536973
- Testing
- ADVM-022
- Where
- 39 sites in United States, France and 1 more
- Volunteers
- 69 people
- Sponsor
- Adverum Biotechnologies, Inc.
Central Serous Chorioretinopathy (CSC)
Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial
Dysregulation of the Angiopoietin-2 (Ang-2)/Tyrosine kinase with Immunoglobulin-like and EGF-like domains 2 (Tie-2) signaling pathway has been implicated in choroidal vascular instability and RPE dysfunction in Central serous…
- Trial name
- NCT07681167
- Testing
- Faricimab
- Volunteers
- 50 people
- Sponsor
- Singapore National Eye Centre
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in participants with neovascular, or exudative (wet), age-related macular degeneration (nAMD).
- Trial name
- NCT04645212
- Testing
- ADVM-022
- Where
- 9 sites in United States
- Volunteers
- 23 people
- Sponsor
- Adverum Biotechnologies, Inc.
Age Related Macular Degeneration, Diabetic Retinopathy
Effect of Video Viewing on Intravitreal Injection Experience
Study Objective The goal of this clinical trial is to evaluate whether viewing a procedural video can improve the patient experience and reduce the incidence and severity of subconjunctival hemorrhage in individuals undergoing…
- Conditions
- Age Related Macular Degeneration, Diabetic Retinopathy, Choroidal Neovascularization, Retinal Vein Occlusion
- Trial name
- NCT07002372
- Testing
- Procedure video viewing
- Where
- China
- Volunteers
- 182 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Neovascular Age-Related Macular Degeneration (nAMD)
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
This Phase 3 study is evaluating the safety and efficacy of 4D-150 versus aflibercept in participants with neovascular age-related macular degeneration (nAMD).
- Trial name
- 4FRONT-2 (NCT07064759)
- Testing
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Where
- 126 sites in United States, Argentina and 15 more
- Volunteers
- 480 people
- Sponsor
- 4D Molecular Therapeutics
Age-Related Macular Degeneration, Neovascularization, Choroidal
Impact of Non-Exudative Type 1 MNV on AMD Progression
The overall goal of the proposed research project is to provide evidence that a specific subtype of neovascularization that may develop in eyes with age-related macular degeneration (AMD) prevents vision loss.
- Trial name
- NCT06125977
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- University of Utah